Research Collaboration and License Agreements - Additional Information (Details)	1 Months Ended	6 Months Ended	12 Months Ended
	Nov. 30, 2017 USD ($) Target	Jun. 30, 2022 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2021 USD ($)	Jul. 31, 2021 USD ($)	Jun. 30, 2021 USD ($)	Dec. 31, 2020 USD ($)	Jun. 30, 2019 USD ($)
Research Collaboration And License Agreements [Line Items]
Collaboration contract asset and other assets		$ 11,700,000			$ 12,500,000		$ 0	$ 0
Pfizer, Inc.
Research Collaboration And License Agreements [Line Items]
Upfront non-refundable payment and certain additional payments received		3,500,000	$ 28,000,000
Pfizer, Inc. \| Collaboration Agreement
Research Collaboration And License Agreements [Line Items]
Contract revenue receivable if milestones achieved or options for all targets exercised						$ 650,000,000
Collaboration agreement direct and incremental costs incurred		12,900,000
Collaboration contract asset and other assets		12,900,000
Pfizer, Inc. \| Regulatory and Sales-Based Milestones \| Maximum
Research Collaboration And License Agreements [Line Items]
Contract revenue receivable if milestones achieved or options for all targets exercised						1,400,000,000
Pfizer, Inc. \| Regulatory Milestone Related to Marketing Approvals
Research Collaboration And License Agreements [Line Items]
Contract revenue receivable if milestones achieved or options for all targets exercised						400,000,000
Pfizer, Inc. \| Sales-Based Milestones
Research Collaboration And License Agreements [Line Items]
Contract revenue receivable if milestones achieved or options for all targets exercised						$ 1,000,000,000
Pfizer, Inc. \| Development Milestone Payments \| Maximum
Research Collaboration And License Agreements [Line Items]
Contract revenue receivable if milestones achieved or options for all targets exercised		225,000,000
Pfizer, Inc. \| Sales Based Milestone Payments
Research Collaboration And License Agreements [Line Items]
Upfront non-refundable payment and certain additional payments received		0
Pfizer, Inc. \| Sales Based Milestone Payments \| Maximum
Research Collaboration And License Agreements [Line Items]
Contract revenue receivable if milestones achieved or options for all targets exercised		550,000,000
Pfizer, Inc. \| Option Payments To License Agreement \| Maximum
Research Collaboration And License Agreements [Line Items]
Contract revenue receivable if milestones achieved or options for all targets exercised		37,500,000
Bayer Collaboration Agreement
Research Collaboration And License Agreements [Line Items]
Contract revenue receivable if milestones achieved or options for all targets exercised									$ 17,500,000
Bayer Collaboration Agreement \| Research Funding Payments
Research Collaboration And License Agreements [Line Items]
Contract revenue receivable if milestones achieved or options for all targets exercised		10,500,000
Bayer Collaboration Agreement \| Research Funding Payments \| Scenario Forecast
Research Collaboration And License Agreements [Line Items]
Contract revenue receivable if milestones achieved or options for all targets exercised				$ 12,000,000
Bayer Collaboration Agreement \| Development Milestone Payments
Research Collaboration And License Agreements [Line Items]
Upfront non-refundable payment and certain additional payments received		0
Bayer Collaboration Agreement \| Development Milestone Payments \| Maximum
Research Collaboration And License Agreements [Line Items]
Contract revenue receivable if milestones achieved or options for all targets exercised									197,500,000
Bayer Collaboration Agreement \| Sales Based Milestone Payments
Research Collaboration And License Agreements [Line Items]
Upfront non-refundable payment and certain additional payments received		0
Bayer Collaboration Agreement \| Sales Based Milestone Payments \| Maximum
Research Collaboration And License Agreements [Line Items]
Contract revenue receivable if milestones achieved or options for all targets exercised									$ 490,000,000
Genentech, Inc. and F. Hoffman-La Roche Ltd.
Research Collaboration And License Agreements [Line Items]
Upfront non-refundable payment and certain additional payments received	$ 34,500,000
Additional upfront non-refundable amount received under previous agreement	$ 11,000,000
Number of designated targets \| Target	10
Genentech, Inc. and F. Hoffman-La Roche Ltd. \| Regulatory Milestone Related to Marketing Approvals
Research Collaboration And License Agreements [Line Items]
Contract revenue receivable if milestones achieved or options for all targets exercised		52,500,000
Genentech, Inc. and F. Hoffman-La Roche Ltd. \| Development Milestone Payments \| Maximum
Research Collaboration And License Agreements [Line Items]
Contract revenue receivable if milestones achieved or options for all targets exercised		44,000,000
Genentech, Inc. and F. Hoffman-La Roche Ltd. \| Option Payments To License Agreement \| Maximum
Research Collaboration And License Agreements [Line Items]
Contract revenue receivable if milestones achieved or options for all targets exercised		27,500,000
Genentech, Inc. and F. Hoffman-La Roche Ltd. \| Commercial Milestones
Research Collaboration And License Agreements [Line Items]
Contract revenue receivable if milestones achieved or options for all targets exercised		60,000,000
Upfront non-refundable payment and certain additional payments received		$ 0